Physician profile
Derek Wayne White
NPI 1619497294
$2,315.34
in general payments reported to CMS, 2019-2025
30 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $172 · 2021: $424 · 2022: $354 · 2023: $425 · 2024: $647 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $320.35 | 2021-2025 | Spravato |
| Novo Nordisk INC | $267.41 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $173.35 | 2022-2025 | Vraylar |
| Exact Sciences Corporation | $148.19 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $147.36 | 2020-2025 | Injectafer |
| Idorsia Pharmaceuticals US INC | $140.90 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $111.29 | 2021-2024 | Camzyos, Eliquis |
| Teva Pharmaceuticals USA, INC. | $105.30 | 2022-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $96.77 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $85.57 | 2024-2025 | Hetlioz, Fanapt |
| Pfizer INC. | $84.31 | 2021-2025 | |
| Glaxosmithkline, LLC. | $63.26 | 2020-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $61.59 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $58.79 | 2020-2022 | |
| Alkermes, INC. | $51.57 | 2023 | Aristada, Lybalvi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.24 | 2022-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $44.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.17 | 2022 | |
| Antares Pharma, INC. | $32.70 | 2024-2025 | Xyosted |
| Axsome Therapeutics, INC. | $32.41 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.00 | 2021 | |
| Eisai INC. | $24.66 | 2021 | |
| Csl Behring | $24.33 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.97 | 2025 | Caplyta |
| Astellas Pharma US INC | $20.01 | 2024 | Veozah |
| Ucb, INC. | $16.54 | 2022 | |
| Currax Pharmaceuticals LLC | $16.37 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.67 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$12,376.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.